Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Urology

Background:

• Phosphodiesterase (PDE) enzymes regulate numerous bodily functions.
• PDE type 5 (PDE5) inhibitors are established treatments for erectile dysfunction (ED).
• Emerging research reveals significant cardiovascular (CV) effects of PDE5 inhibitors.

Purpose of the Study:

• To review recent findings on PDE5 inhibitors and their interaction with the cardiovascular system.
• To explore current and future clinical applications of PDE5 inhibitors beyond ED.
• To discuss the pharmacologic treatment of ED in the context of cardiovascular health.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of data on PDE5 inhibitors' effects on the cardiovascular system.
• Synthesis of information on approved and potential therapeutic uses.

Main Results:

• PDE5 inhibition is effective for idiopathic pulmonary arterial hypertension, with sildenafil and tadalafil approved.
• PDE5 inhibitors demonstrate pleiotropic effects on the cardiovascular system.
• Potential clinical utility is identified for heart failure, coronary artery disease, and hypertension.

Conclusions:

• PDE5 inhibitors offer therapeutic potential for various cardiovascular conditions.
• Understanding the cardiovascular effects of PDE5 inhibitors is crucial for expanding their clinical applications.
• Future research may establish PDE5 inhibitors as key treatments for a broader range of cardiovascular diseases.